3654 results for «382»
3654 results
FFR- and IVUS-guided PCI of a long and calcified LAD lesion - LIVE case
19 May 2026 – From EuroPCR 2026
A 71‑year‑old man with hypertension and dyslipidemia presented with CCS class II angina and three‑vessel coronary artery disease. Functional assessment included CT‑derived micro‑FFR, angiography‑based FFR, and stress myocardial scintigraphy. The only hemodynamically significant lesion was a long, calcified lesion of the LAD.
Lesion preparation was performed with...
Behind standard practice: a place for DCB
19 May 2026 – From EuroPCR 2026
This session examines the role of drug-coated balloons (DCB) beyond standard practice in coronary revascularization. It includes discussions on revascularization strategies in young patients, rescue of early distal LIMA–LAD anastomosis, treatment of in-stent restenosis, stepwise complex CTO bifurcation revascularization using kissing DCBs, and management of calcified...
Identifying problems and solving complex anatomies during TAVI
19 May 2026 – From EuroPCR 2026
A comprehensive session on managing complex anatomies during Transcatheter Aortic Valve Implantation (TAVI), emphasizing risk markers for peri-operative complications and strategies to address difficult anatomical challenges. Real-world cases illustrate practical approaches and key learnings for handling intricate TAVI scenarios.
Mitral TEER beyond the routine: complex and complicated cases
19 May 2026 – From EuroPCR 2026
This session explores complex and complicated cases of mitral transcatheter edge-to-edge repair (TEER) beyond routine practice. It addresses challenges such as device failures, late complications, acute left ventricular dysfunction related to afterload changes, stepwise approaches to overcome procedural failures, rescue strategies in cardiogenic shock, and tailored...
Lessons learned to pave the way for future-proof strategies in TAVI
20 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session focuses on how current experience in transcatheter aortic valve implantation (TAVI) can be translated into more durable strategies for the future, particularly in patients with bicuspid aortic valve disease.
It provides a comprehensive overview of anatomical, clinical, and procedural considerations in this challenging...
From access to reperfusion: a procedural deep dive into pulmonary embolism
20 May 2026 – From EuroPCR 2026
From vascular access to reperfusion strategy, managing acute pulmonary embolism requires rapid decision-making, careful patient selection and increasingly sophisticated interventional techniques.
This EuroPCR 2026 session takes a procedural deep dive into contemporary pulmonary embolism management, focusing on thrombus aspiration techniques and the evolving role of computer-assisted vacuum...
Advancing mitral care with the Intrepid TMVR system
20 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session explores the Intrepid transcatheter mitral valve replacement (TMVR) system and its role in expanding treatment options for patients with mitral regurgitation, including complex anatomies such as mitral annular calcification (MAC).
It highlights how the system’s design features and procedural imaging support a streamlined...
Seeing differently, treating better: advanced imaging shaping modern structural heart practice
20 May 2026 – From EuroPCR 2026
This session explores the transformative role of advanced imaging, particularly 3D intracardiac echocardiography (ICE), in modern structural heart interventions. It provides practical insights into implementation, highlighting how these tools can enhance workflow efficiency and procedural confidence across transcatheter edge-to-edge repair (TEER), left atrial appendage (LAA) closure,...
POPular PAUSE TAVI - Continuation or interruption of oral anticoagulation during TAVI?
02 Sep 2024
Luis Ortega-Paz provides his take on the POPular PAUSE TAVI trial presented by Dirk Jan van Ginkel at the ESC Congress 2024 in London.
Author
OPTIMUM: Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients with Multivessel or Left Main Coronary Artery Disease
04 Nov 2021
Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.
Author
Best of #AHA21 Scientific Sessions: coronary and valvular heart disease trials
14 Nov 2021
Vijay Kunadian provides summaries of study designs and findings in Interventional Cardiology released at the 2021 virtual edition of the American Heart Association Congress. View an infographic of the AVATAR late-breaking trial by Ali Nazmi Calik.
Author
ESC/EACTS Valvular Heart Disease Guidelines 2021: updates from the 2017 Guidelines
29 Aug 2021
There has been significant expansion in the field of structural heart diseases in the last couple of years, generating an extensive body of evidence and warranting an update to the 2017 Guidelines. Mirvat Alasnag provides an analysis of the updates included in this new document - a joint...
Author
Evidence base: current data on TAVI durability and long-term outcomes
18 Jun 2026
This article reviews the current evidence on TAVI durability, focusing on long-term outcomes, device-specific considerations, and the implications for lifetime management strategies.
Author
Author
Early intervention in patients with asymptomatic severe aortic stenosis and left ventricular myocardial fibrosis (EVOLVED)
30 Oct 2024
Ali Nazmi Calik provides his take on the EVOLVED trial presented by Marc Dweck at TCT 2024 in Washington.
Author
